Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alkermes Plc (ALKS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,342,995
  • Shares Outstanding, K 153,780
  • Annual Sales, $ 745,690 K
  • Annual Income, $ -208,440 K
  • 36-Month Beta 2.13
  • Price/Sales 9.91
  • Price/Cash Flow 0.00
  • Price/Book 6.23

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.42 +3.72%
on 11/15/17
56.58 -14.90%
on 10/27/17
-3.33 (-6.47%)
since 10/17/17
3-Month
46.42 +3.72%
on 11/15/17
56.58 -14.90%
on 10/27/17
-2.77 (-5.44%)
since 08/17/17
52-Week
46.42 +3.72%
on 11/15/17
63.40 -24.05%
on 06/09/17
-11.35 (-19.08%)
since 11/17/16

Most Recent Stories

More News
Lifshitz & Miller LLP Announces Investigation of Acorda Therapeutics, Inc., Alkermes plc, ASB Financial Corp., CalAtlantic Group, Capella Education Company, INC Research Holdings, Inc. and YuMe, Inc.

Acorda Therapeutics, Inc. (ACOR)

ASBN : 19.0000 (+0.58%)
CAA : 52.35 (+1.43%)
INCR : 38.10 (+0.26%)
ACOR : 17.85 (+3.48%)
ALKS : 47.99 (+0.50%)
CPLA : 81.20 (-1.87%)
YUME : 3.78 (+1.61%)
Alkermes' New Drug Application for Investigational Product Designed for Initiation Onto ARISTADA(R) Accepted for Filing by U.S. FDA

---- FDA Action Expected by June 30, 2018 --

ALKS : 47.99 (+0.50%)
VIVITROL(R) and Value of Medication-Assisted Treatment for Opioid Dependence Featured in Study Sponsored by National Institute on Drug Abuse

Results from a National Institute on Drug Abuse (NIDA)-funded study, were published in The Lancet today, comparing extended-release naltrexone (VIVITROL(R)) and buprenorphine-naloxone, two...

ALKS : 47.99 (+0.50%)
Allergan's Vraylar Gets FDA Nod for Maintenance Therapy

Allergan's (AGN) schizophrenia capsule, Vraylar, secures an FDA approval for its label expansion as a maintenance treatment option in the market.

AZN : 33.47 (-0.15%)
JNJ : 138.23 (-0.46%)
AGN : 175.94 (+0.65%)
ALKS : 47.99 (+0.50%)
Featured Company News - Alkermes Presents Positive Pre-Clinical Data On Immuno-Oncology Drug Candidate ALKS 4230

Research Desk Line-up: Avadel Pharma Post Earnings Coverage

AVDL : 9.23 (+1.43%)
ALKS : 47.99 (+0.50%)
Alkermes Calls for Impartial National Review of Scientific Data Supporting the Use of FDA-Approved Treatment Options for Opioid Dependence

Amid one of the nation's deadliest and most significant public health crises of our time, Alkermes is calling for a formal review by the National Institutes of Health (NIH) of data related...

ALKS : 47.99 (+0.50%)
Alkermes Reveals Recipients of the 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders

Alkermes plc (NASDAQ: ALKS) today announced the company awarded $1 million in grants to national and local non-profit community organizations for the implementation of innovative,...

ALKS : 47.99 (+0.50%)
Alkermes' Corporate Presentation to be Webcast at the Jefferies 2017 London Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2017 London Healthcare Conference on Wednesday, Nov. 15, 2017 at 2:40...

ALKS : 47.99 (+0.50%)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alkermes plc (ALKS)

NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alkermes plc ("Alkermes" or the "Company") (NASDAQ: ALKS)....

ALKS : 47.99 (+0.50%)
Positive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

Alkermes plc (NASDAQ: ALKS) today announced the presentation of positive preclinical data on the company's immuno-oncology drug candidate, ALKS 4230. Data presented by Dr. Brian Gastman...

ALKS : 47.99 (+0.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication...

See More

Key Turning Points

2nd Resistance Point 49.38
1st Resistance Point 48.56
Last Price 47.99
1st Support Level 47.32
2nd Support Level 46.89

See More

52-Week High 63.40
Fibonacci 61.8% 56.92
Fibonacci 50% 54.91
Fibonacci 38.2% 52.91
Last Price 47.99
52-Week Low 46.42

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart